Carastock.

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties ...Get the latest Cara Therapeutics, Inc. (CARA) stock news and headlines to help you in your trading and investing decisions. Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.Cara Therapeutics Inc (CARA) stock is trading at $5.51 as of 3:36 PM on Tuesday, Mar 21, a gain of $0.21, or 3.96% from the previous closing price of $5.30. The stock has traded between $5.31 and $5.53 so far today. Volume today is below average. So far 335,181 shares have traded compared to average volume of 810,787 shares.Mar 11, 2023 · Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ...

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate …

Aug 24, 2021 · CARA stock was up 2.8% as of Tuesday afternoon. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Earnings Date. Feb 13, 2024 - Feb 19, 2024. Forward Dividend & Yield. 1.84 (16.00%) Ex-Dividend Date. Nov 15, 2023. 1y Target Est. 26.50. Fair Value is the appropriate price for …Thinking of buying or selling Cara Therapeutic stock that’s listed in a currency different from your local one? Use our international stock ticker to check and convert stocks and shares easily in any currency you need.Notably, Cara Therapeutics actually ramped up its cash burn very hard and fast in the last year, by 128%, signifying heavy investment in the business. While that's concerning on it's own, the fact ...CARA 9.28%. 39. See CARA Report. The 37 rating InvestorsObserver gives to Cara Therapeutics Inc ( CARA) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 31 percent of stocks in the Biotechnology industry, CARA’s 37 overall rating means the stock scores better than 37 percent of all stocks.

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties ...

Get the latest Cara Therapeutics Inc. (CARA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Cara stock has gone in circles without any catalysts to help unlock value, but 2022 is full of growth catalysts. Click here to see why I think CARA is a good buy for investors.What is the correlation between Shamrock and Cara stock? Correlation and Covariance: The correlation between two given stocks is determined by taking into account the covariance between them and the standard deviations for each of them. The correlation measure is used to normalize the covariance value and hence its value varies from -1 to …Cara Therapeutics Inc (CARA) stock has fallen -6.06% while the S&P 500 has risen 0.34% as of 12:40 PM on Tuesday, Nov 7. CARA has fallen -$0.08 from the previous closing price of $1.33 on volume of 223,033 shares. Over the past year the S&P 500 has gained 15.08% while CARA has fallen -86.62%. CARA lost -$2.07 per share the …Nov 29, 2023 · Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. CARA stock returns are also predicted based on historical data. According to our research, CARA stock is a bad long-term investment. CARA share price has been in a bear cycle for the past year. Cara Therapeutics, Inc. stock trend is negative. Cara Therapeutics company info. Industry:

Nov 29, 2023 · The Cara Therapeutics stock price fell by -1.90% on the last day (Wednesday, 29th Nov 2023) from $0.98 to $0.96. During the last trading day the stock fluctuated 7.37% from a day low at $0.95 to a day high of $1.02. The price has fallen in 6 of the last 10 days and is down by -12.47% for this period. Volume has increased on the last day by 227 ... Future criteria checks 2/6. Cara Therapeutics is forecast to grow earnings and revenue by 10.7% and 39.6% per annum respectively. EPS is expected to grow by 27.7% per annum. Return on equity is forecast to be -187% in 3 years.Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.Find out the direct holders, institutional holders and mutual fund holders for Cara Therapeutics, Inc. (CARA). Wall Street is positive on Cara Therapeutics Inc (CARA). On average, analysts give Cara Therapeutics Inc a Strong Buy rating. The average price target is $25.5, which means analysts expect th

Find the latest news headlines from Cara Therapeutics, Inc. Common Stock (CARA) at Nasdaq.com.26 thg 3, 2023 ... Tips Cara Stock Opname Efisien untuk Hasil yang Akurat · Hal yang Perlu Dipersiapkan Sebelum Membuat Stock Opname · Pelaksanaan Stock Opname.

CARA's current price target is $15.86. Learn why top analysts are making this stock forecast for Cara Therapeutics at MarketBeat.May 25, 2023 · Simply Wall St. May 25, 2023 at 6:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid ... CARA 9.28%. 39. See CARA Report. The 37 rating InvestorsObserver gives to Cara Therapeutics Inc ( CARA) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 31 percent of stocks in the Biotechnology industry, CARA’s 37 overall rating means the stock scores better than 37 percent of all stocks.Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), MoonLake Immunotherapeutics (MLTX) and Cara Therapeutics (CARA) November 14, 2023TipRanks. Cara shares ‘highly disconnected ...Nov 17, 2023 · finance.yahoo.com - November 14 at 5:00 PM. Cara Therapeutics Stock (NASDAQ:CARA) Earnings Dates and Earning Calls. benzinga.com - November 14 at 7:53 AM. Cara Therapeutics GAAP EPS of -$0.52 beats by $0.01, revenue of $4.87M misses by $5.08M. msn.com - November 13 at 8:53 PM. Browse Getty Images' premium collection of high-quality, authentic Cara stock photos, royalty-free images, and pictures. Cara stock photos are available in ...The FDA has approved Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma AG’s Korsuva (difelikefalin) injection for severe-to-moderate pruritis (itching) in patients with chronic kidney ...Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S.

Based on 2 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $4.00 with a high ...

As of Friday, March 17, Cara Therapeutics Inc’s CARA share price has dipped by 5.19%, which has investors questioning if this is right time to buy.

10.9300. 11.4400. 11.4400. 257,700. *Close price adjusted for splits. **Close price adjusted for splits and dividend and/or capital gain distributions.CARA Stock Analysis - Frequently Asked Questions Is Cara Operations a good dividend stock? Cara Operations (TSE:CARA) pays an annual dividend of C$0.41 per share and currently has a dividend yield of 1.54%.Oct 23, 2023 · Cara Therapeutics Reports Second Quarter 2023 Financial Results. – 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA ® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS ... Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ...Find real-time CARA - Cara Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 5.25 years. total yearly compensation is $2.51M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $84.15K. The average tenure of the management team and the board of …The stock of Cara Therapeutics Inc (CARA) has seen a -11.28% decrease in the past week, with a -16.90% drop in the past month, and a -60.67% decrease in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.66% for CARA.Cara Therapeutics' current financial performance and market outlook do not paint an encouraging picture for investors. Find out why CARA stock is a Sell.What happened. Shares of Cara Therapeutics ( CARA 12.38%) had plunged 27.8% lower as of 10:54 a.m. EST on Tuesday. The big drop came after the drugmaker announced results from a phase 2 clinical ...Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.Cara Therapeutics (CARA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known consensus ...Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...

Dec 1, 2023 · Compare with up to 5 Stocks. On Friday morning 12/01/2023 the Cara Therapeutics Inc share started trading at the price of $0.96. Compared to the closing price on Thursday 11/30/2023 on NAS of $0. ... Thinking of buying or selling Cara Therapeutic stock that’s listed in a currency different from your local one? Use our international stock ticker to check and convert stocks and shares easily in any currency you need.The current Cara Therapeutics [ CARA] share price is $1.09. The Score for CARA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.Instagram:https://instagram. 13 f filingcricket phone payment planlist of health insurance companies in njpaa stock forecast Dec 1, 2023 · View Cara Therapeutics, Inc CARA investment & stock information. Get the latest Cara Therapeutics, Inc CARA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. best stock 2023shares to buy today Nov 13, 2023 · Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend. When is Cara Therapeutics's earnings date? Cara Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off last year's report dates. Learn more on CARA's earnings history. top day trading companies The company, currently valued at $57.32M, closed the recent trade at $1.06 per share which meant it lost -$0.12 on the day or -10.17% during that session. The CARA stock price is -1108.49% off its 52-week high price of $12.81 and 2.83% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find ...Find the latest analyst research for Cara Therapeutics, Inc. Common Stock (CARA) at Nasdaq.com.